# Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma

> **NCT05011227** · PHASE2 · UNKNOWN · sponsor: **Eye & ENT Hospital of Fudan University** · enrollment: 100 (estimated)

## Conditions studied

- Recurrent Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Chemotherapy
- **PROCEDURE:** endoscopic surgery

## Key facts

- **NCT ID:** NCT05011227
- **Lead sponsor:** Eye & ENT Hospital of Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-10
- **Primary completion:** 2025-08-10
- **Final completion:** 2025-08-10
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05011227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05011227, "Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05011227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*